The Role of Tumour Metabolism in Cisplatin Resistance

被引:74
作者
Wang, Lude [1 ]
Zhao, Xiaoya [1 ]
Fu, Jianfei [2 ]
Xu, Wenxia [1 ]
Yuan, Jianlie [3 ]
机构
[1] Zhejiang Univ, Affiliated Jinhua Hosp, Cent Lab, Sch Med, Jinhua, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Jinhua Hosp, Dept Med Oncol, Sch Med, Jinhua, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Jinhua Hosp, Dept Neurosurg, Sch Med, Jinhua, Zhejiang, Peoples R China
关键词
tumour metabolism; cisplatin; resistance; DNA damage repair; ROS; CELL LUNG-CANCER; PHASE-III TRIAL; REPROGRAMMING GLUCOSE-METABOLISM; PLUS CISPLATIN; GASTRIC-CANCER; OPEN-LABEL; MULTIDRUG-RESISTANCE; GLUTAMINE-METABOLISM; MOLECULAR-MECHANISMS; SERINE METABOLISM;
D O I
10.3389/fmolb.2021.691795
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cisplatin is a chemotherapy drug commonly used in cancer treatment. Tumour cells are more sensitive to cisplatin than normal cells. Cisplatin exerts an antitumour effect by interfering with DNA replication and transcription processes. However, the drug-resistance properties of tumour cells often cause loss of cisplatin efficacy and failure of chemotherapy, leading to tumour progression. Owing to the large amounts of energy and compounds required by tumour cells, metabolic reprogramming plays an important part in the occurrence and development of tumours. The interplay between DNA damage repair and metabolism also has an effect on cisplatin resistance; the molecular changes to glucose metabolism, amino acid metabolism, lipid metabolism, and other metabolic pathways affect the cisplatin resistance of tumour cells. Here, we review the mechanism of action of cisplatin, the mechanism of resistance to cisplatin, the role of metabolic remodelling in tumorigenesis and development, and the effects of common metabolic pathways on cisplatin resistance.
引用
收藏
页数:13
相关论文
共 144 条
[1]  
Adra N, 2017, CLIN ADV HEMATOL ONC, V15, P386
[2]   The "Goldilocks Zone" from a redox perspective-Adaptive vs. deleterious responses to oxidative stress in striated muscle [J].
Alleman, Rick J. ;
Katunga, Lalage A. ;
Nelson, Margaret A. M. ;
Brown, David A. ;
Anderson, Ethan J. .
FRONTIERS IN PHYSIOLOGY, 2014, 5
[3]   De nova lipogenesis in health and disease [J].
Ameer, Fatima ;
Scandiuzzi, Lisa ;
Hasnain, Shahida ;
Kalbacher, Hubert ;
Zaidi, Nousheen .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2014, 63 (07) :895-902
[4]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[5]   Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer [J].
Bauerschlag, Dirk O. ;
Maass, Nicolai ;
Leonhardt, Peter ;
Verburg, Frederik A. ;
Pecks, Ulrich ;
Zeppernick, Felix ;
Morgenroth, Agnieszka ;
Mottaghy, Felix M. ;
Tolba, Rene ;
Meinhold-Heerlein, Ivo ;
Braeutigam, Karen .
JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
[6]   Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA [J].
Berndtsson, Maria ;
Hagg, Maria ;
Panaretakis, Theocharis ;
Havelka, Aleksandra Mandic ;
Shoshan, Maria C. ;
Linder, Stig .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (01) :175-180
[7]   Metabolic Reprogramming of Immune Cells in Cancer Progression [J].
Biswas, Subhra K. .
IMMUNITY, 2015, 43 (03) :435-449
[8]   A family of drug transporters: The multidrug resistance-associated proteins [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302
[9]   First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia [J].
Brandes, AA ;
Basso, U ;
Reni, M ;
Vastola, F ;
Tosoni, A ;
Cavallo, G ;
Scopece, L ;
Ferreri, AJ ;
Panucci, MG ;
Monfardini, S ;
Ermani, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1598-1604
[10]   First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].
Carbone, D. P. ;
Reck, M. ;
Paz-Ares, L. ;
Creelan, B. ;
Horn, L. ;
Steins, M. ;
Felip, E. ;
van den Heuvel, M. M. ;
Ciuleanu, T. -E. ;
Badin, F. ;
Ready, N. ;
Hiltermann, T. J. N. ;
Nair, S. ;
Juergens, R. ;
Peters, S. ;
Minenza, E. ;
Wrangle, J. M. ;
Rodriguez-Abreu, D. ;
Borghaei, H. ;
Blumenschein, G. R. ;
Villaruz, L. C. ;
Havel, L. ;
Krejci, J. ;
Corral Jaime, J. ;
Chang, H. ;
Geese, W. J. ;
Bhagavatheeswaran, P. ;
Chen, A. C. ;
Socinski, M. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426